Europe Joint Pain Injection Market to Grow at a CAGR of 8.2% to reach US$ 1,035.54 million from 2021 to 2028

The Europe joint pain injection market is expected to grow from US$ 595.20 million in 2021 to US$ 1,035.54 million by 2028; it is estimated to grow at a CAGR of 8.2% from 2021 to 2028.

Companies operating in the joint pain injection market are undertaking an increasing number of research and development activities to introduce more innovative products. The injection has the ability to restore the viscosity and elasticity of synovial fluid, thereby decreasing pain and inflammation as well as increasing mobility of the affected organ and reducing friction between bones. Additionally, in November 2017, Flexion Therapeutics Inc. launched Zilretta, an intra-articular injection for OA knee pain. It is a non-opioid medicine that has Flexion’s proprietary microsphere technology and offers pain relief for 12 weeks among the patients with osteoarthritis of knee. Furthermore, in July 2019, Teva Pharmaceutical Industries Ltd. launched 1% Sodium Hyaluronate used to treat of patients with OA-related knee pain; the product is especially prescribed to patients who have failed to respond to conservative non-pharmacologic therapy and simple analgesics. Such increasing number of product developments and launches are emerging as an important trend in the joint pain injection market

Several European countries witnessed an unprecedented rise in the number of COVID-19 cases, which led to the discontinuation of several business operations and manufacturing activities of various healthcare products, including joint pain injections, which negatively impacted the joint pain injection market. Also, the pandemic has halted the adoption of new medical device policy and delayed clinical trials and disrupted processes. Two consecutive waves of coronavirus had devastating impact on economic activities in the Europe. Implementation of social distancing and lockdown policies led to closing of orthopedic hospitals and patient visits for elective orthopedic surgeries. This factor negatively impacted the adoption of joint pain injection. In addition, disrupted supply chains, extended lockdowns, and cancelling of orthopedic medical procedures have also negativity affected the growth of the joint pain injection market. The hospitals in the region are cancelling other surgical procedures to keep healthcare facilities free for COVID-19 patients. Moreover, increasing COVID-19 infection in healthcare workers is leading to shortage of staff. These factors are negatively impacting the growth of the joint pain injection market.

With the new advancements and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe joint pain injection market. Musculoskeletal disorders (MSDs) are medical conditions affecting muscles, bones, and joints of neck, shoulders, wrists, back, hips, legs, knees, and feet. These diseases include tendinitis, carpal tunnel syndrome, osteoarthritis, rheumatoid arthritis (RA), fibromyalgia, and bone fractures. As per the World Health Organization (WHO) factsheet updated in 2018, musculoskeletal conditions are the second-largest contributor to disability. According to the same, the prevalence and impact of musculoskeletal disorders is expected to rise with the increase in aging population and rise in the prevalence of risk factors of noncommunicable diseases (NCDs). Further, osteoarthritis (OA) is one of the most common joint disorders, caused by the breakdown of joint cartilage between bones. It is also known as degenerative joint disease or “wear and tear” arthritis. As per the National Health Service (NHS), more than 10 million people in the UK have arthritis or other similar conditions that affect joints. As per the Bupa Health Insurance, osteoarthritis is the most common form of arthritis prevalent in the UK, it affects around the one-third of people aged 45 or more in the country, i.e., ~8.75 million people. Therefore, such high prevalence of musculoskeletal disorders in different countries is increasing the number of treatment procedures being carried out for the same, thereby driving the joint pain injection market growth.
 

Europe Joint Pain Injection Market Segmentation

Europe Joint Pain Injection Market – By Drugs

• Hyaluronic Acid
• Corticosteroid
• Others

Europe Joint Pain Injection Market – By Joint Type

• Knee
• Foot and Ankle
• Shoulder and Elbow
• Hip
• Others

Europe Joint Pain Injection Market – By Distribution Channel

• Retail Pharmacies
• Hospitals Pharmacies
• Others

Europe Joint Pain Injection Market – By Country

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Europe Joint Pain Injection Report Scope